Combined treatment with venetoclax, dasatinib, and FLT3 inhibitors for <i>NUP98‐NSD1</i>+/<i>FLT3‐ITD</i>+ acute myeloid leukemia: A pediatric case report-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combined treatment with venetoclax, dasatinib, and FLT3 inhibitors for NUP98‐NSD1+/FLT3‐ITD+ acute myeloid leukemia: A pediatric case report

Published:2023-03-25 Issue:7 Volume:70 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Wen Xiaojia¹²³⁴^ORCID,Wu Ying¹²³⁴,Huang Pengli¹²³⁴,Zheng Huyong¹²³⁴^ORCID

Affiliation:

1. Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology Beijing China

2. National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics, Capital Medical University Beijing China

3. Key Laboratory of Major Diseases in Children Ministry of Education Beijing China

4. Beijing Children's Hospital, Capital Medical University, National Center for Children's Health Beijing China

Funder

Natural Science Foundation of Beijing Municipality

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.30308

Reference5 articles.

1. MutatedWT1,FLT3-ITD,andNUP98-NSD1Fusion in Various Combinations Define a Poor Prognostic Group in Pediatric Acute Myeloid Leukemia

2. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial

3. Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia

4. Single‐center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia

5. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Venetoclax: a new player in the treatment of children with high-risk myeloid malignancies?;Blood Advances;2024-07-09

2. The landscape of NUP98 rearrangements clinical characteristics and treatment response from 1491 acute leukemia patients;Blood Cancer Journal;2024-05-14

3. Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies;International Journal of Molecular Sciences;2023-11-24

4. Pediatric acute myeloid leukemia – novel approaches;Current Opinion in Hematology;2023-11-20

5. Redefining Cancer Therapy: Toward BCL-XL/BCL-2 Dual Inhibitors with Diminished Platelet Toxicity;ACS Medicinal Chemistry Letters;2023-08-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3